Advertisement

Topics

The top 5 most promising drugs (February 2014)

00:15 EDT 27th May 2017 | BioPortfolio

THE FIVE MOST PROMISING DRUGS LAUNCHED OR RECEIVING APPROVAL February 2014

Drug Disease Company
Gazyva Chronic lymphocytic leukemia Biogen Idec/Genentech/
F. Hoffman-La Roche
Vitekta HIV Japan Tobacco/Gilead Sciences
Valchlor Stage IA and IB mycosis fungoides-type cutaneous T-cell lymphoma Ceptaris Therapeutics
Opsumit® Pulmonary arterial hypertension Actelion
NovoEight® Factor VIII deficiency Novo Nordisk

Topics to Watch:

• Orphan Drugs – Roche subsidiary Genentech, and Biogen Idec launched  Gazyva™, an anti-CD20 humanized IgF1 monoclonal antibody launched for the treatment of chronic lymphocytic leukemia (CLL), and Valchlor™, the first and only FDA-approved topical formulation of mechlorethamine for stage IA and IB mycosis fungoides-type cutaneous T-cell lymphoma, launched by Actelion.

• Alzheimer’s Disease – H.Lundbeck and Otsuka are developing Lu-AE58054, a selective antagonist of the 5-HT6 receptor which modulates neurotransmitter systems and is expressed in areas of the brain involved in cognition, entered phase III trials. If successful, worldwide sales of the drug are expected to reach $176 million in 2018.

• Scar Prevention – RXi Pharmaceuticals’ RXI-109 entered a phase II trial for the prevention of scar tissue formation. Scar prevention and reduction is an area of high unmet need, with no FDA-approved therapeutics available for post-operative scars.

Source: Thomson Reuters Cortellis Competitive Intelligence

Quick Search
Advertisement
 

review and buy The top 5 most promising drugs (February 2014) market research data and corporate reports here